Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SSR128129E |
Synonyms | |
Therapy Description |
SSR128129E is an allosteric pan-FGFR inhibitor which may inhibit angiogenesis and tumor growth (PMID: 23597562, PMID: 24760775, PMID: 29656465, PMID: 27479031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SSR128129E | FGFR Inhibitor (Pan) 26 | SSR128129E is an allosteric pan-FGFR inhibitor which may inhibit angiogenesis and tumor growth (PMID: 23597562, PMID: 24760775, PMID: 29656465, PMID: 27479031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 K650E | myeloid neoplasm | no benefit | SSR128129E | Preclinical | Actionable | In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562). | 23597562 |
FGFR3 wild-type | myeloid neoplasm | sensitive | SSR128129E | Preclinical | Actionable | In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562). | 23597562 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|